|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 April 2007, Vol. 109, No. 8, pp. 3300-3307. Prepublished online as a Blood First Edition Paper on December 19, 2006; DOI 10.1182/blood-2006-06-028001.
IMMUNOBIOLOGY Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin1 Department of Microbiology and Immunology, University of North Carolina, Chapel Hill; 2 Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh; and 3 Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh
CD8+ cytotoxic T lymphocytes (CTLs) are important effector cells responsible for tissue destruction in several autoimmune and allograft-related diseases. To discover if pathogenic T cells could be selectively deleted, we investigated the ability of a toxin coupled to major histocompatibility complex (MHC) class I tetramers to kill antigen-specific CD8+ T cells. H2-Db tetramers were assembled using streptavidin conjugated to the ribosome-inactivating protein (RIP) saporin (SAP). These tetramers inhibited ribosome activity in vitro, retained the T-cell receptor (TCR)–binding specificity of their nontoxic counterparts, and were internalized by 100% of target cells, leading to cell death in 72 hours. Cytotoxicity was dependent on the tetramer dose and avidity for the T cell. A single injection of the SAP-coupled tetramer eliminated more than 75% of cognate, but not control, T cells. This work demonstrates the therapeutic potential of cytotoxic tetramers to selectively eradicate pathogenic clonotypes while leaving overall T-cell immunity intact.
Autoimmune diseases such as type 1 diabetes mellitus and multiple sclerosis result from chronic organ-specific damage mediated by autoreactive T cells. Ideally, treatment of these conditions would prevent or disable the inciting mechanisms, but at present, the underlying causes remain unknown. Even if available, such therapy likely would be inadequate for treating clinical disease because once initiated, autoaggressive T-cell responses can be self-perpetuating,1 and an efficient means of halting ongoing immune attack will also be needed for successful treatment. In analogous fashion, normal T-cell activity can have pathologic consequences in allotransplantation settings, leading to graft rejection, or in bone marrow recipients, to acute or chronic graft-versus-host disease. Prevention or treatment of injurious T-cell responses in transplantation patients with nonspecific immunosuppressive agents, such as glucocorticoids, calcineurin inhibitors, or antimetabolites, is variably successful, requires long-term administration, and poses risks of toxicity, infection, and malignancy.2–8 In T-cell–mediated autoimmune diseases, significant improvements in outcome with these drugs have not been reported; hence, given the hazards, their use is not advocated.9,10 There is increasing evidence that CD8+ T cells are the important mediators of tissue destruction in type 1 diabetes mellitus11–13 and multiple sclerosis;14–16 therefore, selective deletion of pathogenic cytotoxic T lymphocyte (CTL) clonotypes might constitute an effective treatment. Similarly, elimination of graft- or host-reactive CD8+ T-cell populations could prevent complications associated with allotransplantation. T-cell clones are distinguished by their unique surface T-cell receptors (TCRs), which bind to a particular peptide–major histocompatibility complex (pMHC) molecule combination. Specific CD8+ T cells in mixed populations can therefore be identified with fluorophore-labeled, soluble tetrameric complexes of pMHC class I molecules (tetramers).17 In addition to marking particular clonotypes, tetramer-TCR interactions mimic binding of native ligands, leading to intracellular signaling, activation, differentiation, and proliferation.18 Previously, we have shown that a single injection of tetramer primes T cells in vivo, while repetitive administration has a tolerizing effect on alloreactivity.19,20 The ability to modulate specific CD8+ T-cell activity in vivo suggested that tetramers might be a useful therapeutic approach for targeting pathogenic T cells. We reasoned that tetramer-mediated delivery of a cytotoxic molecule would result in selective T-cell deletion. To test this possibility, we produced H2-Db tetramers coupled to saporin (SAP), a potent type I ribosome-inactivating protein (RIP). Construction of a radioactive tetramer for killing CD8+ T cells was recently described.21 Here we show that a SAP-coupled tetramer specifically binds and is internalized by the cognate T cell, resulting in cell death by 72 hours. We also demonstrate that a single injection of a SAP-coupled tetramer was capable of eliminating more than 75% of target T cells in vivo.
Mice C57BL/6J mice were obtained from The Jackson Laboratory (Bar Harbor, ME). TCR-transgenic B6.D2 TgN(Tcr-Lcmv)327Sdz/Fre mice (designated as P14), and B6 TgN(Tcr-HY) mice that had been backcrossed to C57BL/6J-rag-1tm1 recombinase-deficient mice (designated as H-Y), were bred in-house, as described previously.18 P14 mice were crossed with C57BL/6-Tg(H2Kb-GFP)/Fre mice that express green fluorescent protein (GFP) under control of the H2-Kb promoter22 to produce P14.GFP mice.23 All transgenic mice were phenotyped by flow cytometry of peripheral blood T cells. Mice were housed in a specific pathogen–free laboratory animal facility that is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), and typically were used in experiments at 6 to 8 weeks of age. Experimental procedures were reviewed and approved by the University of North Carolina–Chapel Hill (UNC-CH) Institutional Animal Care and Use Committee (IACUC), and adhered to published principles of laboratory animal care. Preparation of peptides and tetramers
The H2-Db–restricted peptide epitopes flu (ASNENMETM) and gp33 (KAVYNFATC), the gp33 altered peptide ligands (APLs) C9M and K1S, and the H-Y APL C2A (KASRNRQYL) were synthesized at the UNC-CH Peptide Synthesis Facility, purified by reversed-phase high-pressure liquid chromatography, and dissolved in dimethyl sulfoxide at 10 mg/mL. Murine H2-Db monomers were produced by folding recombinant Purification of CD8+ T cells Spleens from donor mice were aseptically collected in PBS containing 0.5% fetal bovine serum (FBS), disaggregated, and depleted of erythrocytes using ammonium chloride lysis buffer (0.15 M NH4Cl4, 1 mM KHCO3, and 0.1 mM Na2EDTA). Splenocytes were enriched for CD8+ T cells by negative selection using a CD8+ T-cell isolation microbead cocktail over a QuadroMACS magnetic separator (Miltenyi Biotec, Sunnyvale, CA). The naive phenotype (CD25–CD44lo CD62Lhi CD69–) and purity (approximately 90% for P14 and P14.GFP; approximately 50% for H-Y) of each preparation was confirmed by flow cytometry. Primary T-cell cultures Enriched CD8+ T cells (1.25-2.5 x 104/well) were incubated at 37°C in RPMI 1640 medium supplemented with 10% FBS, 5 x 10–5 M 2-mercaptoethanol, 2 mM L-glutamine, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer, 100 µg/mL streptomycin, and 100 IU/mL penicillin (R-10) in duplicate or triplicate 200-µL cultures in 96-well flat-bottomed plates. In cytotoxicity experiments, R-10 medium contained 20 ng/mL murine interleukin (IL)–7 (Peprotech, Rocky Hill, NJ). Tetramers were added to a final concentration of 5 nM unless otherwise indicated, and were removed after 2 hours by repeated washing with R-10 prior to additional incubation. Adoptive transfer and tetramer injections Enriched CD8+ T cells (2 x 105-1 x 107/mouse) were washed and resuspended in PBS, and injected intravenously (200 µL) via the lateral tail vein. Similarly, tetramers (22.2-44.4 pM) were diluted in PBS and injected intravenously (200 µL) or into the footpad (25 µL). Cell staining and flow cytometry
Single-cell suspensions from both in vitro and in vivo experiments were washed in fluorescence-activated cell sorter (FACS) buffer (2% FBS and 0.1% NaN3 in PBS) and stained with fluorochrome-conjugated or biotinylated antibodies (Abs), or PE-conjugated tetramers, for 15 to 30 minutes at 4°C in a 96-well round-bottomed plate. Secondary staining with SA–Alexa Fluor 488 or SA–allophycocyanin (APC) was performed identically, and cells were fixed with 1% buffered formaldehyde. For internalization experiments, T cells were incubated for 5 minutes in either FACS buffer or in 0.5 M NaCl/0.5 M acetic acid (pH 2.5) prior to analysis. For determination of mitochondrial membrane potential ( Tetramer toxicity After baseline body weights and blood samples were obtained, C57BL/6J mice were randomly assigned to 1 of 3 treatment groups, receiving either nontoxic tetramer (22.2 pM) or SAP-coupled tetramer at low (22.2 pM) or high (66.6 pM) dose. Venous blood was collected from the superficial temporal vein ("submandibular" bleeding) using a 5-mm Goldenrod lancet (MEDIpoint Inc, Mineola, NY) 2, 7, and 12 days after injection. Serum was separated from the clot by centrifugation (12 500 rpm for 20 minutes) and stored frozen at –20°C. Samples (25 µL per mouse) from each time point were pooled by treatment group and assayed for creatinine, total bilirubin, and alanine aminotransferase (ALT) activity with a Roche/Hitachi 912 chemistry analyzer (Basel, Switzerland). Mice were weighed 3 times weekly through day 24 and at death on day 30. At that time, the left liver lobe and left kidney were removed, halved, fixed with 10% buffered formalin, and embedded in paraffin. Mounted sections (4 µm in thickness) were stained with hematoxylin and eosin and evaluated in blinded fashion by a board-certified veterinary pathologist (J.M.C.). Confocal microscopy Following 30 minutes of loading with unlabeled or PE-labeled tetramers at 4°C, and 1 hour of incubation at 37°C, acid-stripped and washed P14 T cells were permeabilized using a Cytofix/Cytoperm kit (BD Biosciences) and successively stained with a rat anti-CD107a mAb (1D4B), a biotinylated antirat mAb (RG7/1.30), and SA–Alexa Fluor 647. T cells were subsequently incubated for 10 minutes with DAPI (4,6 diamidino-2-phenylindole; Molecular Probes) in PBS/10 mM glycine, resuspended in FluorSave reagent (Calbiochem, San Diego, CA), mounted on glass slides, and coverslipped. Images were acquired at 22°C on a Zeiss Axioplan 2 microscope (Everest Digital Microscopy Workstation; Intelligent Imaging Innovations, Denver, CO) with DIC, DAPI, Cy3, and Cy5 filters, using a 63x/1.4 numerical aperture oil objective and a Photometrics CoolSNAP HQ camera (Photometrics, Tucson, AZ). Image stacks were deconvolved using Slidebook 3.0.10 software (Intelligent Imaging Innovations), and stored in TIFF format. Statistical analyses Data were analyzed using Prism 4.0 (GraphPad Software, San Diego, CA). Dose-response curves for cytotoxic tetramers were established by sigmoid curve-fitting, and EC50 values were determined by nonlinear regression analysis. Differences in means between treatments were calculated, as appropriate, by either 2-tailed t test, or analysis of variance (ANOVA) procedure with the Dunnett multiple comparisons post test. In all analyses, the level of significance was set at a P value less than .05, and graphical results are displayed as the arithmetic mean ± standard error.
CD8+ T cells internalize surface-bound MHC class I tetramer
To select an appropriate (ie, surface- or internally active) toxin for construction of a cytotoxic tetramer, it was necessary to determine the fate of bound tetramer. To accomplish this, we used P14 T cells, which bear a transgenic
A SAP-coupled tetramer is internalized after TCR-specific binding Based on these results, we prepared a candidate cytotoxic tetramer by coupling biotinylated pMHC monomers to a SA-SAP conjugate molecule. Ribosome-inactivating toxins such as SAP cause cell death by cleaving an adenosine in 28S rRNA, irreversibly inhibiting protein synthesis. In their native form, type I RIPs are relatively nontoxic because of their inability to bind and enter mammalian cells. Coupling of SA-SAP to pMHC molecules did not diminish its toxicity, as demonstrated by the similar degree of ribosome inhibition by gpC9M-SAP and the parent SA-SAP in a cell-free translation assay (Figure 2A). To verify that tetramers prepared with SA-SAP could still bind cognate CD8+ T cells, P14 T cells were incubated with gpC9M-SAP, hyC2A-SAP, or gpC9M plus a molar equivalent of free (unconjugated) SAP. Subsequent staining with anti-SAP Abs shows that antigen-restricted binding was preserved (Figure 2B). It was also possible that a SAP-coupled tetramer could bind to other cell types via interactions with the SAP or SA molecules.30 Using the same Ab-staining technique, however, we did not find binding of the SAP-coupled tetramer to other immune cells (Figure 2C), suggesting that bystander toxicity would be minimal.
To establish that the SAP-coupled tetramer was internalized efficiently, we again compared the fate of bound tetramer on quiescent (4°C) and metabolically active (37°C) T cells. Cold P14 T cells were initially incubated with gpC9M, gpC9M-SAP, or hyC2A-SAP, followed by FITC-labeled anti-SAP Abs, and then, to amplify the signal, by PE-labeled anti-FITC Abs. After additional incubation at the indicated temperatures, we found acid-resistant PE fluorescence, corresponding to the SAP moiety, in all active T cells exposed to the cognate SAP-coupled tetramer (Figure 2D). A SAP-coupled tetramer selectively deletes antigen-specific T cells in vitro
We then evaluated the ability of the Db-SAP tetramer to kill target T cells. To accomplish this, it was necessary to compare relative T-cell survival above the background level of activation-induced cell death (AICD) that results from strong TCR stimulation. Because SAP-mediated toxicity depends on internalization, we hypothesized that P14 T-cell cultures exposed to the control tetramer hyC2A-SAP, or to free SAP mixed with the cognate tetramer gpC9M, would not exhibit greater cell loss than those treated with gpC9M alone. The cytotoxicity of hyC2A-SAP was verified by including H-Y T cells in the assay. To determine if killing was selective, the 2 target populations were cultured together and treated with mixtures of gpC9M and hyC2A tetramers to ensure that all T cells were exposed to identical concentrations of their cognate tetramers. To measure survival, we quantified live cells by exclusion of the impermeant nucleic acid dye 7-AAD. Flow cytometry dotplots (Figure 3A) show the deletion of V
Primary T cells cultured in vitro also can die from neglect, and it is possible that SAP-coupled tetramers caused the death of cognate T cells simply by providing inadequate stimulation through the TCR. To exclude this possibility, we first compared surface activation markers on T cells after incubation with nontoxic and cytotoxic tetramers. P14 T cells exposed to gpC9M or gpC9M-SAP showed equivalent changes in the expression of CD62L and CD69 (Figure 3B), and CD25 and CD44 (not shown). When incubated with the control tetramer hyC2A (not shown), P14 T cells displayed the same naive phenotype as freshly isolated cells, or those cultured in medium alone. H-Y T cells incubated with hyC2A and hyC2A-SAP also showed identical changes in activation markers (not shown). Upon stimulation with antigen, naive CD8+ T cells exhibit an increase in   m,31 which can be measured using the potential-sensitive cationic dye DiIC . P14 T cells cultured with gpC9M or gpC9M-SAP demonstrated equivalent increases in the mean fluorescence intensity of DiIC (Figure 3C). Together, these data indicate that SAP-coupled tetramers provide the same magnitude of TCR stimulation as the corresponding nontoxic ligand. These experiments also show that not all targeted T cells were eliminated by the cytotoxic tetramer (Figure 3A). This incomplete effect could have reflected an insufficient dose, a toxin-resistant subpopulation, or evaluation at a premature time point. Because internalization studies suggested that, at the tetramer dose used, all T cells appeared to have endocytosed a similar, presumably lethal quantity of SAP (Figure 2D), we first investigated the kinetics of cell killing in separate, side-by-side P14 and H-Y cultures. The time course of H-Y T-cell death is shown in representative dotplots (Figure 4A). By 72 hours, more than 98% of input H-Y or P14 T cells were killed by the cognate cytotoxic tetramer (Figure 4B). Similar results were also found in experiments using H2-Kd–restricted, TCR-transgenic CD8+ T cells and Kd-SAP tetramers (not shown).
Internalization of the SAP-coupled tetramer occurs within 1 to 2 hours (Figure 1C). To determine how rapidly initial tetramer binding occurs, we exposed P14 T cells to gpC9M-SAP and washed the cell pellets immediately, or 7.5, 15, 30, 60, or 120 minutes later. There was no difference in cell killing among any of the treatment groups at 48 hours (not shown), indicating that a lethal number of cytotoxic complexes binds almost instantly to TCRs, and are subsequently endocytosed. The efficiency of T-cell deletion depends on tetramer avidity and dose
Because TCR binding is necessary for killing, we reasoned that the cytotoxicity of a SAP-coupled tetramer would depend partly on the avidity of the T cell–tetramer interaction. To investigate this, we prepared additional P14-specific tetramers from pMHC monomers folded with the native gp33 peptide and the weak agonist APL K1S (gpK1S), and from a mutated H2-Db molecule (containing an
A SAP-coupled tetramer deletes Ag-specific T cells in vivo Last, we evaluated the ability of the Db-SAP tetramer to delete cognate CD8+ T cells in vivo. An equal mixture of female P14.GFP and H-Y T cells were adoptively transferred into C57BL/6J mice, and after allowing 24 hours for redistribution, recipients were injected with gpC9M or gpC9M-SAP. The tetramer dose (22.2 pM) provided an approximate SAP dose of 0.085 mg/kg, which is well below the LD50 of 0.4 to 1.0 mg/kg reported for mAb-SAP immunotoxins.32,33 A single injection of gpC9M-SAP tetramer selectively deleted more than 75% of target T cells within 72 hours (Figure 6A-B). The percentage and number of control H-Y T cells did not differ between groups, indicating that the loss of P14.GFP T cells with gpC9M administration could not be attributed to inefficient adoptive transfer or poor cell recovery. No overt signs of toxicity were observed with treatment. To assess potential acute or chronic adverse effects of the immunotoxin, a Db-SAP tetramer was given at either the dose effective at deleting T cells (22.2 pM), or at a 3-fold–increased dose (66.6 pM). Following injection, mice were monitored for change in body weight, which is a sensitive indicator of rodent health, and for biochemical and histologic evidence of injury to the liver or kidney, which are reported to be the target organs of SAP.34 Even with administration of the higher dose, no behavioral signs of illness were noted, although a decrease in body weight was seen (Figure 7A). The onset and resolution of weight loss was temporally correlated with a transient hepatopathy marked by elevated serum concentrations of the liver-specific cytosolic enzyme ALT (Figure 7B, top panel). With the low dose of SAP-coupled tetramer, the increase in ALT was mild and short-lived. No changes in serum total bilirubin (Figure 7B, bottom panel) accompanied treatment, and the livers of all mice appeared histologically normal when evaluated 30 days after injection. Several mice that received the high dose of cytotoxic tetramer had isolated small renal tubules containing acellular casts. This change was not observed with low-dose administration, and in all groups, serum creatinine remained normal (<17.68 µM [0.2 mg/dL]) at all time points.
We used an MHC class I tetramer for selective delivery of a cytotoxic molecule to T cells. H2-Db tetramers linked to a Type 1 RIP bound, activated, and were internalized by cognate T cells to the same degree as traditional, fluorophore-labeled tetramers. SAP-coupled tetramers specific for P14 and H-Y TCRs selectively deleted target T cells in mixed-cell cultures. In vivo administration of the Db-SAP tetramer reduced antigen-specific T cells in the spleen by more than 75%. A tetramer-directed toxin could represent a potent new technology for eliminating specific deleterious T-cell responses in autoimmune and transplantation-related diseases. Among the most significant recent advances in the treatment of cancer are Ab-targeted therapies, capable of selectively destroying neoplastic cells. For lymphoid malignancies, these agents include the anti-CD20 mAbs rituximab, ibritumomab (90Y-congugated), and tositumomab (131I-congugated);36,37 the anti-CD22 mAb epratuzumab;38 and the anti-CD52 mAb alemtuzumab.39 Unfortunately, to date, the use of Ab-based deletional therapies to induce T-cell tolerance has not produced equivalent clinical successes. Neither alemtuzumab nor antithymocyte globulin treatment, for example, have improved long-term outcomes in multiple sclerosis or diabetes mellitus.40,41 While effective in preventing graft rejection, administration of these relatively nonselective agents also carries risks of delayed immune recovery and serious opportunistic infections.42,43 Development of an agent capable of targeting specific T cells therefore remains a critical therapeutic objective. Experimental studies evaluating the killing of T cells with immunotoxins have been reported previously. Typically, the specificity of these conjugates is determined by a surface antigen that defines a subpopulation rather than a clonotype. For example, activated T cells have been targeted with anti-CD25 or anti-CD152 (CTLA-4) mAbs linked to SAP.44,45 As pharmacologic agents, such immunotoxins would offer little gain in selectivity over currently available immunosuppressive drugs, and the benefit of eliminating auto- or graft-reactive CTLs could be outweighed by the unintended deletion of regulatory T cells bearing the same markers. While generation of a mAb-directed immunotoxin against a particular TCR is possible, the technical difficulty in preparing native idiotype protein for immunization precludes ready implementation of this approach. The feasibility of using pMHC targeting to kill specific T cells was demonstrated recently using tetramers conjugated to the cytotoxic alpha-particle emitter actinum-225, although in vivo effects were not evaluated.21 In addition to their clonotypic specificity and relative ease of preparation, T-cell immunotoxins constructed from pMHC molecules possess other potential advantages over their mAb-based counterparts. Within a heterogeneous population of specific auto- or graft-reactive CD8+ T cells, some pathogenic TCRs may be sufficiently distinct antigenically from the representative idiotype to escape recognition by an anti-idiotype mAb immunotoxin. Consequently, such treatment would rapidly select for the immunotoxin-resistant clone. In contrast, by mimicking the natural TCR ligand, a cytotoxic tetramer can effectively target virtually all functionally relevant, deleterious T cells. Because the cytotoxicity of the SAP-coupled tetramer depends on its avidity for the T cell (Figure 5B; Table 1), however, it is likely that a small percentage of low-avidity, antigen-specific T cells will not be killed. Paradoxically, such permissiveness may be beneficial in the treatment of some autoimmune diseases. In one animal model, the occupancy of target organs with low-avidity, clonotypic CD8+ T cells following selective eradication of high-avidity effectors prevented overt disease, while more extensive deletion did not.46 The sparing of protective T cells might be enhanced by altering the avidity of the tetramer, which can be accomplished quite easily by substitution of APLs for the native epitope. Several obstacles could hinder the successful use of a cytotoxic tetramer. Binding to surface molecules independent of the TCR may lead to endocytosis and lethal effects in nontarget cells. For example, sufficient SAP-coupled tetramer might bind via the CD8 coreceptor alone to kill noncognate T cells. In our study, however, we did not observe nonspecific tetramer binding, consistent with other reports,17,47 nor did we find nonselective cytotoxicity in mixed T-cell experiments. If this interaction ultimately proves to be consequential, then tetramers can be prepared using mutated heavy chains that abrogate MHC-CD8 binding, which appears unnecessary for killing (Figure 5B; Table 1). The increase in serum ALT activity that we observed (Figure 7B; top panel) indicates that hepatocytes are nonspecific targets of the SAP-coupled tetramer, similar to findings with mAb-based immunotoxins.34 The rapid return of hepatic enzyme activity to the normal range, together with the absence of any histologic changes, suggests that the liver insult mediated by the cytotoxic tetramer, even at 3 times the effective dose, is reversible. Nevertheless, it should also be noted that, while SAP is a convenient toxin to establish the proof of principle of a cytotoxic tetramer, therapeutic use of this type I RIP might not be optimal. It is conceivable, for example, that pMHC-guided delivery of an agent that disables vital T-cell–specific intracellular pathways could be equally as effective while minimizing or preventing systemic toxicity. A second obstacle is the tetramer-mediated activation of target T cells, which would be harmful if killing is inefficient. Binding of the TCR by tetramers or mAbs can initiate intracellular signaling cascades, leading to priming and expansion. The SAP-coupled tetramers stimulated T cells equally as well as nontoxic tetramers (Figure 3B), and while essentially all targets were killed in vitro (Figure 4B), P14 T cells were still recoverable 3 days after a single injection of gpC9M-SAP (Figure 6A). Determining the functional phenotype of these surviving T cells will be an important next step in assessing this potential hazard, which might be overcome by taking advantage of the relatively simple means (in contrast to mAbs) of manipulating tetramer-binding characteristics. Thus, tetramers folded with candidate APLs could be screened in vitro for T-cell binding, stimulation, and cytotoxicity, allowing the selection of antagonist peptides that result in efficient killing with minimal activation.48,49 Last, the survival of some target T cells after 1 injection of tetramer suggests that complete eradication may require multiple doses, which we are currently investigating. A possible consequence of repeated administration is the development of Abs against nonself-components of the tetramer, which is a well-recognized obstacle to extended treatment with conventional immunotoxins. The inherent flexibility of the tetramer system may provide an answer for this problem by allowing simple substitution of less-immunogenic components: for example, by using DNA, rather than streptavidin, to form pMHC multimers and link the toxic moiety. This study demonstrates that tetrameric pMHC complexes can deliver a lethal dose of toxin to specific T cells in vitro and in vivo, with minimal bystander killing. By deleting pathogenic T-cell populations to induce specific tolerance, such cytotoxic tetramers should prove very useful as primary therapy for selected immune-mediated diseases.
Author contributions: P.R.H. designed research, performed experiments, and wrote the paper; C.B., M.D.W., and M.D.L.J. performed research (monomer preparation, confocal microscopy, and animal care and phenotyping); J.M.C. performed histopathologic analyses; E.J.C. and J.A.F. contributed reagents and participated in experiment design and data analysis; and all authors reviewed the final version of the manuscript. Conflict-of-interest statement: The authors declare no competing financial interests. Correspondence: Paul R. Hess, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Box 8401, 4700 Hillsborough St, Raleigh, NC 27606; e-mail: paul_hess{at}ncsu.edu.
We thank Denise Higgins at Advanced Targeting Systems for assistance with the ribosome inhibition assay. Supported by a National Institutes of Health (NIH) grant R01 GM 067143 (J.A.F.) and a Juvenile Diabetes Research Foundation grant (P.R.H.).
Submitted June 8, 2006; accepted December 12, 2006.
Prepublished online as Blood First Edition Paper, December 19, 2006
DOI: 10.1182/blood-2006-06-028001
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top
Abstract
Introduction
-chains purified from Escherichia coli inclusion bodies with ß2 microglobulin and synthetic peptide. Preparation of the mutated D227K H2-Db molecule was described previously.
m (measured as increased DiIC
